Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: An animal model of Parkinson's disease

Behavioural Brain Research

Volumn 122, Issue 1, 2001, Pages 79-92

  Rodríguez Díaz, Manuel ^a   Abdala, Patricio ^a   Barroso Chinea, Pedro ^a,b   Obeso, José ^c   González Hernández, Tomás ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

6 OHDA; Animal model; Cell vulnerability; Dopamine; Parkinson's disease

Indexed keywords

APOMORPHINE; DOPAMINE RECEPTOR STIMULATING AGENT; NORTRIPTYLINE; OXIDOPAMINE;

ANIMAL MODEL; ARTICLE; BRAIN REGION; CATALEPSY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; HYPOKINESIA; INTRACEREBRAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MASTICATION; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

ADRENERGIC AGENTS; ANIMALS; BRAIN; CELL COUNT; DISEASE MODELS, ANIMAL; DOPAMINE; INJECTIONS, INTRAVENTRICULAR; LOCOMOTION; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0035077354     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(01)00168-1     Document Type: Article

References (104)

1. Behavioural lateralization in rats: prenatal stress effects on sex differences
2. Sex differences in behavioural despair: Relationships between behavioural despair and open field activity
3. The neurokinin1 receptor antagonist CP-99,994 reduces catalepsy produced by the dopamine D2 receptor antagonist raclopride: correlation with extracellular acetylcholine levels in striatum
4. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations
5. Enhancement of audiogenic seizure by 6-hydroxydopamine
6. Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine
7. Developmental characteristics of brain catecholamines and tyrosine hydroxylase in the rat: effects of 6-hydroxydopamine
8. Behavioural differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symtoms in clinical syndromes with reduced brain dopamine
9. The rotating 6-hydroxydopamine-lesioned mouse as a model for assessing functional effects of neuronal grafting
10. Undrugged rotational response in nigro-striatal system-lesioned rats is related with the previous early response to apomorphine when repeatedly administered
11. Conditioning the early behavioural response in the Rotational model of Parkinson's disease
12. Quinolinic acid lessions of rat striatum abolish D1- and D2-dopamine receptor-mediated catalepsy
13. Clozapine: neuroleptic-induced EPS and tardive dyskinesia
14. Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage interval
15. Anatomical analysis of the involvement of mesolimbocortical dopamine in the locomotor stimulant actions of d-amphetamine and apomorphine
16. Enhanced behavioural depressant effects of reserpine and α-methyl-tyrosine after 6-hydroxydopamine treatment
17. Comparison of the behavioural depressant effects of biogenic amine depleting and neuroleptic agents following various 6-hydroxydopamine treatments
18. Alteration of avoidance and ingestive behaviour after destruction of central catecholamine pathways with 6-hydroxydopamine
19. Catalepsy and circling behaviour after intracerebral injections of neuroleptic, cholinergic and anticholinergic agents into the caudate-putamen, globus pallidus and substantia nigra of rat brain
20. Mapping of globus pallidus and ventral pallidum lesion that produce hyperkinetic treading
21. The substantia nigra of the human brain II. Nigrosomes and the nigral matrix, a compartimental organization based on calbindin D28k immunohistochemistry
22. The substantia nigra of the human brain II. Patterns of loss of dopamine-containing neurons in Parkinson's disease
23. The role of D1 and D2 dopamine receptors in oral stereotypy induced by dopaminergic stimulation of the ventrolateral striatum
24. Preferential vulnerability of A8 dopamine neurons in the primate to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
25. Parkinsonism upturned wolking stick as aid to locomotion
26. Effects of 6-hydroxydopamine on CNS catecholamines, spontaneous motor activity and amphetamine-induced hyperactivity in rats
27. Ageing and Parkinson's disease: substantia nigra regional selectivity
28. Intrecerebral SCH 23390 and catalepsy in the rat
29. Early behavioural effects of intraventricular administration of 6-hydroxydopamine in rat
30. Decreased intracranial self-stimulation after neuroleptics or 6-hydroxydopamine: evidence for mediation by motor deficits rather than reduced reward
31. Intracerebral SCH 23390 and catalepsy in the rat
32. Involvement of pallidal and nigral GABA mechanisms in the generation of tremulous jaw movements in the rats
33. Decreased locomotor and investigatory exploration after denervation of catecholamine terminal field in forebrain of rats
34. An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine
35. D1 and D2 dopamine receptors regulated gene expression of striatonigral and striatipallidal neurons
36. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridene-induced parkinsonian syndrome in macaca fascicularis: which midbrain dopaminergic neurons are loss?
37. Midbrain dopaminergic neurons (nuclei A8, A9 and A10): three-dimensional reconstruction in the rat
38. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization
39. Compartmental organization and chemical profile of dopaminergic and GABAergic neurons in the substantia nigra of the rat
40. Neuropaphology of immunohistochemically identified brainstem neurons in Parkinson's disease
41. Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease
42. Zur normalatomie der substantia nigra. Versuch einer architektonischen Gliederung
43. Zur pathologie der paralysis agitants und des postenzephalitischen Parkinsonismus
44. The effects of globus pallidus lesions on dopamine-dependent motor behaviour in rats
45. Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity
46. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
47. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapiramidal side effect liability
48. Effect of selective destruction of central and peripheral catecholamine-containing neurones with 6-hydroxydopamine on catecholamine excretion in the rat
49. Effect of some centrally acting agents in rats after intraventricular injections of 6-hydroxydopamine
50. Is the mesocortical dopaminergic system involved in Parkinson's disease?
51. Microtopography of tyrosine hydroxylase, glutamic acid decarboxylase, and choline acetyltransferase in the substantia nigra and ventral tegmental tegmental area of control and Parkinsonian brains
52. Distribution of catecholamines in the ventral mesencephalon of human brain, with special reference to Parkinson's disease
53. Pathology of Parkinson's disease. Changes other that the nigrostriatal pathway
54. Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: possible relation to Parkinsonian symptoms
55. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum
56. Paradoxical kinesia in Parkinsonism is not caused by dopamine release
57. Characterization of behavioural and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat
58. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications
59. Chronic parkinsonism in human due to a product of meperidine-analog synthesis
60. Effects of intraventricular 2, 4, 5-trihydroxyphenylethylamine (6-hydroxydopamine) on rat behaviour and brain catecholamine metabolism
61. Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene
62. D2 dopamine receptor gene expression by cholinergic neurons in the rat striatum
63. Central effects of 6-hydroxydopamine
64. Effect of ventral tegmental 6-hydroxydopamine lesions on the locomotor stimulant action of nicotine in rats
65. The effects of 6-hydroxydopamine pretreatment on the accumulation of Dopa and dopamine in the brain and peripheral organs following L-Dopa administration
66. Tremolous jaw movements produced by acute tacrine administration: possible relation to parkinsonian side effects
67. Rate of cell death in parkinsonism indicate active neuropathological process
68. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease
69. Catecholamines and neurologic diseases
70. Dopaminergic deficiency is more pronounced in putamen than in nucleus caudatus in Parkinson's patients
71. Pathophysiology of levodopa-induced dyskinesia in PD: problems with the current model
72. Self-injurious behaviour and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 2. Intracerebral microinjectioon of dopamine agonists and antagonists
73. Etiology and pathogenesis of Parkinson's disease
74. D1- and D1-receptor antagonist induce catalepsy via different efferent. Striatal pathways
75. Striatal and nucleus accumbemns D1/D2 dopamine receptors in neuroleptic catalepsy
76. The absolute number of nerve cells in substantia nigra in normal subjects and in Parkinson's disease estimated with an unbiased sterological method
77. A 6-hydroxydopamine-induced selective parkinsonian rat model
78. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease
79. The neurotoxin MPTP does not reproduce in the rhesus monkey the interrregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease
80. Discriminative and motor performance in rats after interference with dopamine neurotransmission with spiroperidol
81. Apomorphine lowers dopamine synthesis for up to 48 hours: implications for drug sensization
82. The catalepsy test: its ups and downs
83. Mechanisms of action of 6-hydroxydopamine
84. Behavioural and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat
85. Tremulous jaw movements in rats: a model of parkinsonian tremor
86. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxudopamine: a combined retrograde tracing and immunocytochemical study in the rat
87. Akinesia Paradoxica. Electroencephalogr
88. Effects pf smood, motivation, stress, and alertness on the performance in Parkinson's disease
89. A model for multisystem evaluation treatment of individuals with Parkinson's disease
90. Effect of 6-hydroxydopamine on some actions of tremorine and oxotremorine
91. Parkinsonism: facilitation of motion by sensory stimulation
92. Cross-sensitization between footschock stress and apomorphine on self-injurious behaviour and neostriatal catecholamines in a rat model of Lesch-Nyhan syndrome
93. MPTP produces a pattern of nigrostriatal degeneration which coincides with mosaic organization of the caudate nucleus
94. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions
95. Is interruption of the nigros-triatal dopamine system producing 'lateral hypothalamic syndrom'?
96. Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system
97. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour
98. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system
99. Adipsoia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system
100. Effect of L-DOPA on the locomotor activity of rats pretreated with 6-hydroxydopamine
101. Amine accumulation in behavioural pathology
102. MPTP produces a mosaic-like pattern of terminal degeneration in the caudate nucleus of dog
103. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28k
104. Recovery of feeding and drinking by rats after intraventricular 6-hydroxydopamine or lateral hypothalamic lesions